RxDoctor Payments Data

Jennifer Jimenez Madrigal

Family · Miami Beach, FLNPI 1639651383

Payments from drug & device makers

$2,831in general payments, 2019–2025

Across 119 payments — averaging $23.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$515
  • Astellas Pharma US Inc$351
  • Takeda Pharmaceuticals U.S.A., Inc.$174
  • Sanofi$107
  • Boehringer Ingelheim$92
  • plus $484 from 13 others

What the payments were for

  • Food & beverage$2,54390%
  • Education$28910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,831 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$4,504
Medicare patients
26
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$40,877
LokelmaSodium Zirconium Cyclosilicate13$15,206
Breo ElliptaFluticasone/Vilanterol33$14,000
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$12,782
Tacrolimus30$3,397
Azithromycin37$1,049
Albuterol Sulfate HfaAlbuterol Sulfate24$553
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim56$395
Levothyroxine Sodium12$366
Montelukast Sodium14$276
Gabapentin11$223
Prednisone21$198
Pravastatin Sodium13$194
Fluticasone Propionate20$186
Pantoprazole Sodium27$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,109$67,660104 claims
AstraZenecaLokelma$515$15,20613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.

Other family in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →